The purpose of this study is to explore virtual reality (VR) exposure for the treatment of vaginismus, also known as fear of painful vaginal penetration. Vaginismus is common and affected individuals experience difficulties with vaginal intercourse and gynaecological exams. Available treatments are not very effective. Cognitive behavioural therapy with an exposure element (insertion of vaginal dilators in the presence of a clinician) is highly effective, but unavailable in Canada.
Participate in Men's and Women's Health studies at VCHRI.
The purpose of this study is to evaluate two online psychological programs that address sexual concerns in women. Both programs have been found to be effective for sexual concerns when administered in face-to-face programs. However, many women lack access to these face-to-face interventions, which leaves them unable to access the care they need. These treatments have been adapted to online delivery in a program called eSense, and the eventual goal is to make these helpful treatments more accessible.
The purpose of this study is to is to examine the effects of 12 weeks of high intensity interval training on the cognitive health of perimenopausal woman.
The purpose of this study is to evaluate the impact of an aerobic exercise intervention on Chemotherapy-Related Cognitive Changes (CRCC) in women diagnosed with breast cancer who undergo chemotherapy.
The purpose of this study is to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.
TrueNTH (True North) Peer Navigation is a new study that puts trained prostate cancer survivors and caregivers in touch with patients and caregivers looking for support. Peer navigators will help prostate cancer patients and caregivers navigate their journey through cancer care, from the point of diagnosis to treatment and beyond and will provide emotional, practical, and informational support. This work was awarded by Prostate Cancer Canada and is proudly funded by the Movember Foundation.
Feasibility of using the ARES Device to measure sleep in men with prostate cancer starting androgen deprivation therapy
The primary purpose of our study is to examine the feasibility of using the ARESTM device to measure sleep parameters of PCa patients who are on ADT. In addition, we will also assess the feasibility of obtaining serial questionnaires from patients. In this small pilot study, we will describe subjective sleep quality, morphometric measures, urinary symptoms, hot flashes, and weight gain.
The goal of the current study is to determine the prevalence, rate, and types of pregnancy complications and early life events that may be associated with the emergence of psychosis and related metabolic disorder in patients with schizophrenia spectrum disorders.
The Women's HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in women with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 3 years.
Prostate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to these needs through survivorship care. The current randomized control trail (RCT) will focus on the development and evaluation of a facilitated electronic Prostate Cancer Survivorship Care Plan (PC-SCP).
Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2)
This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome.
This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression) who are in remission from an episode. Participants who show cognitive impairment at the screening visit will be enrolled into the study and randomized at the baseline visit to receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and / or are candidates for active surveillance, but have planned to undergo radical prostatectomy. In these patients, the results may be used to help estimate the risk of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology.
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)
The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research study is to learn if treatment with standard systemic therapy in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety of this treatment combination will also be studied.
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer (EMMPC)
The investigators aim to evaluate the feasibility of a larger clinical trial assessing an exercise program during the "teachable moment" in patients with prostate cancer and measuring its effect on tumor apoptosis signaling, lipogenesis and steroidogenesis. Participants will be randomized between a 8-12 week exercise program or to standard of care only. Participants will be assessed at screening, baseline (day 0), throughout the trial intervention (days 1-84), post-intervention visit (prior to radical prostatectomy) and final study visit 6-months post-radical prostatectomy.
At the Falls Prevention Clinic, each subject receives a comprehensive assessment of his or her individual risk factors for falling in addition to a comprehensive medical examination. Recommendations and appropriate follow up tests and referrals are ordered for patients on an individual basis.